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torvastatin Improves Left Ventricular
ystolic Function and Serum Markers
f Inflammation in Nonischemic Heart Failure
rikanth Sola, MD,* Muhammad Q. S. Mir, MD,* Stamatios Lerakis, MD, FACC,
eeraj Tandon, MD, FACC,† Bobby V. Khan, MD, PHD*
tlanta, Georgia; and Shreveport, Louisiana
OBJECTIVES This study examined the effect of statin therapy on vascular markers of inflammation and
echocardiographic findings in patients with nonischemic forms of cardiomyopathy.
BACKGROUND Despite advances in therapy, morbidity and mortality from heart failure (HF) remain high.
We wished to determine whether treatment with atorvastatin affects left ventricular (LV)
systolic function and markers of inflammation in patients with nonischemic HF.
METHODS A total of 108 patients with nonischemic HF and a left ventricular ejection fraction (LVEF)
35% were randomized to either atorvastatin 20 mg/day or placebo in a double-blinded
fashion for a 12-month period. The LVEF and LV end-diastolic diameter (LVEDD) and left
ventricular end-systolic diameter (LVESD) were determined by echocardiography. Serum
markers of inflammation and oxidation were also measured.
RESULTS The LVEF increased from 0.33  0.05 to 0.37  0.04 (p  0.01) in the atorvastatin group
over the 12-month follow-up period, whereas those patients in the placebo group experienced
a decline in ejection fraction during the same time period. In addition, LVEDD was reduced
from 57.1  5.9 mm to 53.4  5.1 mm (p  0.007) and LVESD was reduced from 42.4 
3.8 mm to 39.1 3.8 mm (p 0.02) in the cohort of patients treated with atorvastatin; these
dimensions increased in the placebo group. There was an increase in erythrocyte superoxide
dismutase (E-SOD) activity, and there were significant reductions in serum levels of high
sensitivity C-reactive protein, interleukin-6 (IL-6), and tumor necrosis factor-alpha receptor
II (TNF- RII) in the atorvastatin group.
CONCLUSIONS The use of atorvastatin in patients with nonischemic HF improves LVEF and attenuates
adverse LV remodeling. The effects on soluble levels of several inflammatory markers with
atorvastatin suggest, in part, mechanisms by which statins might exert their beneficial effects
in nonischemic HF. (J Am Coll Cardiol 2006;47:332–7) © 2006 by the American College
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.06.088of Cardiology Foundation
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mespite advances in pharmacological and interventional
herapy, morbidity and mortality due to heart failure (HF)
emain high. Patients with HF often have elevated levels of
ro-inflammatory cytokines and chemokines, compounds
hat are involved in adverse left ventricular (LV) remodel-
ng, neurohormonal activation, impaired autonomic and
See page 342
ascular tone, and progression of coronary atherosclerosis
1). Higher levels of these inflammatory markers, including
umor necrosis factor-alpha, interleukin (IL)-6, and
-reactive protein, are also associated with adverse cardio-
ascular morbidity and mortality (2–4).
Hydroxymethylglutaryl CoA reductase inhibitors (statins)
ave been shown to reduce morbidity and mortality in
From the *Division of Cardiology, Emory University School of Medicine, Atlanta,
eorgia; and the †Division of Cardiology, Louisiana State University Health Sciences
enter, Shreveport, Louisiana. Dr. Khan has been an advisory board member for
anofi-Aventis and Bristol Myers Squibb and on the speakers bureau for Sanofi-
ventis, Bristol Myers Squibb, and Takeda Pharmaceuticals.e
Manuscript received March 24, 2005; revised manuscript received June 6, 2005,
ccepted June 14, 2005.oronary artery disease (CAD) and other atherosclerosis-
elated diseases (5–8); however, only limited data are
vailable on the effect of statins in reducing adverse cardio-
ascular events in patients with HF (9,10). Statins have
any effects beyond lipid-lowering that make them of
otential benefit in patients with HF of both ischemic and
onischemic etiologies. Statins facilitate nitric oxide (NO)
ynthesis and improve endothelial function, both of which
re typically impaired in patients with HF (11,12). In
ddition, they inhibit the synthesis of inflammatory cyto-
ines and chemokines, improve autonomic function, and
everse myocardial remodeling (13,14). Moreover, statins
ight retard the progression of myocardial dysfunction in
F by promoting plaque stabilization and reducing the
rogress of CAD.
We hypothesized that statin therapy would improve LV
unction and markers of inflammation in patients with
onischemic etiologies of HF. We undertook the present
ilot study to evaluate the effects of therapy with atorvasta-
in on echocardiographic indexes of LV function and serum
arkers of inflammation in patients with nonischemic
tiologies of HF and systolic dysfunction.
MS
e
A
n
(
v
3
e
r
2
h
n
h
s
t
w
S
d
m
p
w
s
d
s
s
e
s
h
n
s
w
i
E
t
m
m
T
o
m
S
(
(
T
m
r
b
p
r
L
l
c
w
a
C
d
i
r
i
T
o
t
a
p
o
s
a
m
i
i
b
n
t
l
s
L
s
S
s
p
i
c
t
c
t
w
(
a
s
w
S
R
S
333JACC Vol. 47, No. 2, 2006 Sola et al.
January 17, 2006:332–7 Statins and HFETHODS
ubjects. Men and women ages 18 years or older were
ligible for enrollment if they had: 1) New York Heart
ssociation (NYHA) functional class II to IV HF due to a
onischemic etiology; 2) left ventricular ejection fraction
LVEF) of 35%, as documented by echocardiography or
entriculography during the one year before enrollment; and
) stable doses of HF medications for three months before
nrollment. Patients were excluded if they: 1) had been
eceiving a statin during the six months before enrollment;
) had had a prior adverse event related to statin use; or 3)
ad diabetes mellitus. Patients were classified as having
onischemic cardiomyopathy if they had no prior clinical
istory of a myocardial infarction and no coronary artery
tenoses 50% on cardiac catheterization performed during
he one year before enrollment. Written informed consent
as obtained from all patients.
tudy design. Patients (n  108) were randomized in a
ouble-blinded fashion to either atorvastatin (20 mg/day) or
atching placebo for a 12-month period. Study visits took
lace at 0, 6, and 12 months. Transthoracic echocardiography
as performed at each study visit, and LVEF, LV mass/body
urface area, and LV systolic and diastolic diameters were
etermined. Blood was drawn at each study visit to measure
everal markers of inflammation. The primary end point of the
tudy was change in LVEF, as determined by transthoracic
chocardiography. Secondary end points included changes in
everal markers of inflammation and/or oxidation, including
igh sensitivity C reactive protein (hsCRP), IL-6, tumor
ecrosis factor- receptor II (TNF- RII), and erythrocyte
uperoxide dismutase (E-SOD). The study protocol complies
ith the Declaration of Helsinki and was approved by the
nstitutional review board.
chocardiographic assessment. Two-dimensional trans-
horacic echocardiograms were performed at 0, 6, and 12
onths. Left ventricular systolic function and cardiac di-
ensions indexed to body surface area were determined.
he heart was imaged in parasternal short axis view to
btain LV wall thickness and parasternal long axis view to
easure ejection fraction, which was determined with
Abbreviations and Acronyms
CAD  coronary artery disease
E-SOD  erythrocyte superoxide dismutase
HDL  high-density lipoprotein
HF  heart failure
hsCRP  high sensitivity C-reactive protein
IL  interleukin
LDL  low-density lipoprotein
LV  left ventricle/ventricular
LVEDD  left ventricular end-diastolic diameter
LVEF  left ventricular ejection fraction
LVESD  left ventricular end-systolic diameter
TNF- RII  tumor necrosis factor-alpha receptor IIimpson’s rule. Left ventricular end-diastolic diameter mLVEDD) and left ventricular end-systolic diameter
LVESD) diameters were measured fromM-mode tracings.
he LV mass index was calculated by the Penn-cube
ethod, as previously described (15). The images were
eviewed by two independent echocardiographers who were
linded to the subject’s clinical status during the study
eriod, and any discrepancies in interpretations were
esolved.
aboratory measurements. Laboratory samples were col-
ected at each study visit and stored at 80°C after
entrifugation. An aliquot was drawn, and E-SOD activity
as determined with hemolysates and commercially avail-
ble kits (Cat. No. SDI 25, Randox Lab. Ltd., Crumlin,
ounty Antrim, Ireland). Briefly, superoxide radicals pro-
uced by xanthine and xanthine oxidase reacts with 2-(4-
odophenyl)-3-(4-nitrophenol)-5-phenyltetrazolium chlo-
ide to form a red formazan dye (16). The E-SOD activity
s then measured by the degree of inhibition of this reaction.
he E-SOD activity was expressed as U/g Hb. For analysis
f serum IL-6, studies were performed on each sample in
riplicate. Sixty microliters of serum were used for analysis,
nd enzyme-linked immunosorbent assay (ELISA) was
erformed. The levels of total serum IL-6 were determined
n a plate reader at an optical density of 420 nm. High
ensitivity CRP was measured with an immunoprecipitation
ssay. Serum TNF- RII was measured as an indirect
arker of monocyte/macrophage stimulation (17). The
nterassay variability was10% and the intra-assay variabil-
ty was 5% for all four markers. We found no interference
y atorvastatin or its metabolites in these assays.
Blood glucose was measured with a glucose dehydroge-
ase method after precipitation of proteins by trichloroace-
ic acid. Low-density lipoprotein (LDL) and high-density
ipoprotein (HDL) fractions were separated from fresh
erum by combined ultracentrifugation and precipitation.
ipoprotein fraction cholesterol and triglycerides were mea-
ured enzymatically.
tatistical analysis. All values presented are the mean 
tandard deviation for continuous variables and as the
ercentage of total patients for categorical variables. The
ndependent sample t test and chi-square were used for
omparison of continuous and categorical variables, respec-
ively. Two-way analysis of variance (ANOVA) was used to
ompare laboratory and serial echocardiographic data be-
ween the groups. Data were analyzed by intention to treat,
ith a secondary analysis performed with paired samples
patients with complete baseline and follow-up data avail-
ble). A p value of 0.05 was considered statistically
ignificant, and all p values were two-sided. Calculations
ere performed with Statistical Package for the Social
ciences (SPSS) software (version 10.0, Chicago, Illinois).
ESULTS
tudy population. One hundred and eight patients (67
en and 41 women) were enrolled in the study and followed
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Statins and HF January 17, 2006:332–7or 12  2 months. Of these patients, 54 each were
andomized to the placebo and atorvastatin groups. At
aseline, there was no significant difference in NYHA
unctional class, baseline LVEF, LDL cholesterol, HDL
holesterol, or triglyceride levels between the two groups, as
hown in Table 1.
A total of 89 patients (placebo  43, atorvastatin  46)
ompleted the 12-month treatment period. The remaining
9 subjects dropped out of the study by their choice or the
ecision of the patient’s attending physician. Data are
resented for those subjects who completed the study. At
he end of the 12-month study period, there was a signifi-
ant reduction in both LDL cholesterol level (2.4  0.4
mol/l for atorvastatin vs. 2.9  0.4 mmol/l for placebo;
 0.0001) and serum triglyceride levels (1.5 0.2 mmol/l
or atorvastatin vs. 1.7 0.2 mmol/l for placebo; p 0.003)
n the atorvastatin versus the placebo groups. There was no
hange in serum HDL cholesterol levels in either group
Table 2).
torvastatin improves LV systolic function. In the group
andomized to atorvastatin, there was an increase in LVEF
able 1. Baseline Patient Demographics and Characteristics
Placebo
(n  54)
Atorvastatin
(n  54)
ge (yrs) 54.1  6.9 53.3  6.2
ale (%) 33 (62) 34 (64)
ody mass index (kg/m2) 24.4  3.8 24.1  4.0
ystolic BP (mm Hg) 119  11 116  11
iastolic BP (mm Hg) 72  10 75  9
jection fraction 0.33  0.04 0.33  0.05
YHA functional class II (%) 26 30
YHA functional class III (%) 70 64
YHA functional class IV (%) 4 6
aseline laboratory values
LDL cholesterol (mg/dl) 124  20 118  15
HDL cholesterol (mg/dl) 42  8 44  7
Triglycerides (mg/dl) 144  23 149  19
Fasting glucose (mg/dl) 93  15 91  19
Hemoglobin A1C (%) 5.0  0.7 4.9  0.6
aseline medications
ACE inhibitor or ARB (%) 49 (91) 46 (85)
Beta-blocker (%) 39 (72) 36 (67)
Aldosterone blocker (%) 6 (11) 5 (9)
Diuretics (%) 35 (65) 35 (65)
 NS for difference in baseline characteristics between the study cohorts. Values are
(%) or mean  SD.
ACE angiotensin-converting enzyme; ARB angiotensin receptor blocker; BP
blood pressure; HDL high-density lipoprotein; LDL low-density lipoprotein;
YHA  New York Heart Association.
able 2. Changes in Serum Cholesterol Levels With Treatment
Baseline
Placebo
(n  54)
Atorvastatin
(n  54)
DL cholesterol (mg/dl) 124  20 118  15
DL cholesterol (mg/dl) 42  8 44  7
riglycerides (mg/dl) 144  23 149  19alues are mean  SD. Baseline p values were determined by an unpaired t test; changes bet
Abbreviations as in Table 1.rom 0.33 0.05 to 0.37 0.05 (p 0.01), whereas LVEF
ecreased from 0.33  0.04 to 0.31  0.03 (p  0.04) in
hose patients randomized to placebo (Fig. 1). At the end of
he 12-month study period, patients in the atorvastatin
roup had a statistically significant higher ejection fraction
han patients randomized to placebo (0.37  0.05 vs. 0.31
0.03, respectively; ANOVA, p  0.004). In addition,
here were statistically significant decreases in both
VEDD and LVESD in the atorvastatin group after
reatment, whereas these dimensions actually increased for
atients randomized to placebo (Table 3). Between the
lacebo and atorvastatin groups, the differences in both
VEDD (ANOVA, p  0.01) and LVESD (ANOVA,
 0.01) were statistically significant. The LV mass/body
urface area did not change significantly in either group.
tatistical comparisons were similar with analysis using
ntention to treat and by paired samples.
torvastatin reduces soluble levels of IL-6, TNF- RII,
nd hsCRP and increases E-SOD activity. In patients
reated with atorvastatin, serum soluble levels of IL-6
Follow-Up
p Value
Placebo
(n  43)
Atorvastatin
(n  46) p Value
NS 124  17 93  9 0.0001
NS 43  8 46  8 NS
NS 149  22 138  20 0.003
igure 1. Change in ejection fraction in the placebo and atorvastatin
roups during the 12-month study follow up. *p  0.01 for the difference
n ejection fraction between baseline and 6 or 12 months within the
torvastatin group; †p 0.04 for the difference in ejection fraction between
aseline and 12 months within the placebo group; ‡p  0.004 for the
ifference in ejection fraction at 12 months between the placebo and the
torvastatin groups.ween the two groups from baseline were determined by two-way analysis of variance.
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January 17, 2006:332–7 Statins and HFecreased from 17.1  1.4 ng/dl to 13.3  0.8 ng/dl over
he 12-month study period, with no significant change in
he placebo group (Table 4). Similar reductions in serum
evels of TNF- RII and hsCRP were noted in the
torvastatin group, with no significant change in the placebo
roup. Activity of E-SOD, an anti-oxidative marker, was
ower in the atorvastatin group at baseline when compared
ith placebo (550  58 U/g Hb for atorvastatin vs. 580 
0 U/g Hb for placebo; p  0.009) but increased signifi-
antly in the atorvastatin group at the end of the follow-up
eriod (649  43 U/g Hb for atorvastatin vs. 577  38 U/g
b for placebo; p  0.0001).
torvastatin therapy and clinical events. At the end of
he 12-month study period, the mean NYHA functional
lass was 2.9 0.3 in the placebo group vs. 2.2 0.3 in the
torvastatin group (p 0.001). There were 13 hospital stays
or HF among those subjects in the placebo group vs. 8
ospital stays for HF in the atorvastatin group (p  NS).
here was no difference in total mortality between the two
tudy groups (four in each group).
ISCUSSION
his study shows a substantial benefit with atorvastatin
herapy in patients with systolic HF due to a nonischemic
tiology. The LV systolic function improved significantly in
he cohort of patients treated with atorvastatin, compared
ith a decline in systolic function in patients treated with
lacebo over the 12-month study period. In addition, there
ere reductions in both LV end-diastolic and end-systolic
imensions in the atorvastatin group when compared with
lacebo. These findings suggest that atorvastatin might
etard the progression of adverse myocardial remodeling in
able 3. Effects of Atorvastatin on Left Ventricular Dimensions
Baseline
Placebo
(n  54)
Atorvastatin
(n  54)
V mass/body surface
area (g/m2)
117  22 115  18
VEDD (mm) 56.1  5.9 57.1  5.9
VESD (mm) 40.9  4.7 42.4  3.8
jection fraction 0.33  0.04 0.33  0.05
alues are mean  SD. Baseline p values were determined by an unpaired t test; chan
LVEDD  left ventricle end-diastolic diameter; LVESD  left ventricle end sy
able 4. Changes in Markers of Inflammation and Oxidation
Baseline
Placebo
(n  54)
Atorvastatin
(n  54)
sCRP (mg/dl) 1.9  0.4 2.0  0.4
L-6 (ng/dl) 17.1  1.4 16.7  1.3
NF- RII (ng/dl) 33.4  4.2 33.3  3.2
rythrocyte superoxide
dismutase (U/g Hb)
580  60 550  58alues are mean  SD. Baseline p values were determined by an unpaired t test; changes bet
hsCRP  high sensitivity C-reactive protein; IL-6  interleukin-6; TNF- RII  tumatients with nonischemic HF. Finally, atorvastatin therapy
as associated with reductions in levels of hsCRP, TNF-
II, and IL-6 as well as an increase in E-SOD activity,
uggesting an association between changes in pro-
nflammatory and pro-oxidative markers and LV systolic
unction.
The patients in our study were largely either NYHA
unctional class II or III in symptoms. Baseline medical
herapy was good, with 88% of the study population
eceiving either an angiotensin-converting enzyme inhibitor
r angiotensin receptor blocker and 69% receiving a beta-
locker at the time of enrollment. Mean baseline LDL and
DL cholesterol values were 3.2  0.5 mmol/l and 1.1 
.2 mmol/l, respectively, suggesting that the benefits of
torvastatin therapy in patients with nonischemic HF occur
t cholesterol values that are below the current National
holesterol Education Program III guidelines for the ini-
iation of lipid-lowering therapy.
Currently, few data are available on the effects of statins
n patients with nonischemic etiologies of HF. The major
tatin trials have generally excluded patients with HF,
lthough subanalyses of data from several of these studies
ave found that statin therapy reduces the risk of developing
schemic HF in patients with prior CAD (18,19). Several
on-randomized comparisons, such as the Prospective Ran-
omized Amlodipine Survival Evaluation (PRAISE) and
he Antiarrhythmics Versus Implantable Defibrillators
AVID) trials, demonstrated a mortality benefit in patients
ith ischemic and/or nonischemic HF who were treated
ith statins (20–24).
The data from our study also confirm the results of a
andomized trial by Node et al. (25), in which 53 subjects
Follow-Up
p Value
Placebo
(n  43)
Atorvastatin
(n  46) p Value
NS 118  14 113  13 0.1
NS 60.3  5.1 53.4  5.1 0.01
NS 43.1  4.5 39.1  3.8 0.01
NS 0.31  0.03 0.37  0.04 0.004
ween the two groups from baseline were determined by two-way analysis of variance.
iameter.
Follow-Up
p Value
Placebo
(n  43)
Atorvastatin
(n  46) p Value
NS 1.9  0.3 1.7  0.2 0.002
NS 17.3  1.4 13.3  0.8 0.001
NS 34.5  3.0 24.3  2.3 0.001
0.009 577  38 649  43 0.0001ween the two groups from baseline were determined by two-way analysis of variance.
or necrosis factor-alpha receptor II.
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Statins and HF January 17, 2006:332–7ith nonischemic dilated cardiomyopathy were randomized
o simvastatin 10 mg/day versus matching placebo for 14
eeks. The authors found that patients treated with simva-
tatin had a lower NYHA functional class compared with
atients receiving placebo (2.04 0.06 vs. 2.32 0.05, p
.01), which corresponded to an improved LVEF in the
imvastatin group (34  3% to 41  4%, p  0.05) but not
n the placebo group. In addition, plasma concentrations of
NF-, IL-6, and B-type natriuretic peptide were signifi-
antly lower in the simvastatin group compared with the
lacebo group. Taken together, the results of these two
andomized trials suggest that statins might have a role in
mproving symptoms and blunting the pro-inflammatory
tate in patients with nonischemic HF.
nflammation in HF. Inflammatory mediators play an
mportant role in the development and progression of HF.
hese mediators, or cytokines, are generally pharmacolog-
cally active proteins that are secreted by a variety of cell
ypes in response to a variety of stimuli. Among the
ytokines, TNF- plays an important role in the progres-
ion of HF. Tumor necrosis factor-alpha has been impli-
ated in the development of LV dysfunction, pathologic LV
emodeling, endothelial dysfunction, increased cardiac myo-
yte apoptosis, and the development of anorexia and ca-
hexia, among other effects (26,27) The reproducibility of
lasma concentrations of soluble TNF receptors, however,
re much higher than that of TNF- itself and might
xplain why soluble TNF receptors such as TNF- RII
redict both short-term (28) and long-term (29) prognosis
etter than TNF- in HF patients. Other cytokines, such as
L-6, are involved in myocyte hypertrophy, myocardial
ysfunction, and muscle wasting. Higher levels of IL-6, as
ell as the inflammatory marker CRP, are associated with a
oorer prognosis in HF patients (2–4).
Statins have important anti-inflammatory effects and
ownregulate CRP and inflammatory cytokines, which are
ctivated in HF of any etiology (13) Our data showed a
eduction in serum levels of hsCRP as well as TNF- RII
nd IL-6 in patients with HF treated with statins. In
ddition, statin treatment was associated with an increase in
-SOD activity, suggesting that statins also have antioxi-
ant activity in this patient population. Erythrocyte super-
xide dismutase catalyzes the reaction of superoxide anions
O2) to hydrogen peroxide (H2O2), making it a central
lement in the maintenance of the vascular redox balance.
s such, superoxide dismutase is indirectly involved in
egulating levels of nitric oxide bioavailability. Other inves-
igators have found that statin therapy lowers systemic levels
f protein-bound nitrotyrosine (NO2Tyr), a marker for
xidant stress mediated via pathways involving NO-derived
xidants (30,31).
In addition to their anti-inflammatory and antioxidant
ffects, there are a number of other potential mechanisms that
ight account for the beneficial effects of statin therapy
bserved in this study. These include the inhibition of athero-
clerosis as well as the direct effects of lipid lowering and plaquetabilization, attenuation of pathological myocardial remodel-
ng, improvement of endothelial dysfunction, and inhibition of
eurohormonal activation (13,14,32,33).
tudy limitations. Our study has several limitations that
ust be noted. As a pilot study that focused on mechanisms
f action, the number of subjects was small (n  108) and
ollow-up was limited to 12 months. Thus, the study was
ot powered to evaluate the effect of atorvastatin on clinical
utcomes in this patient population. Similarly, data on the
ffects of atorvastatin in patients with both nonischemic HF
nd diabetes are not available, because many patients with
nown diabetes are already on a statin, which was an
xclusion criterion in our study. Nevertheless, the results of
his study suggest that therapy with atorvastatin might be of
enefit in patients with nonischemic HF and systolic
ysfunction. A large-scale randomized trial of statins in this
atient population is warranted.
onclusions. Currently, only 20% to 30% of patients with
onischemic HF receive statin therapy, compared with
pproximately 50% to 55% of those with an ischemic
tiology of HF and 80% to 85% of patients with CAD
34,35). Our findings suggest that the use of atorvastatin in
atients with nonischemic HF and systolic dysfunction is
ssociated with an improvement in LV dysfunction, an
ttenuation of adverse LV remodeling, and an improvement
n HF symptoms (NYHA functional class). The anti-
nflammatory and antioxidative effects of statins might play
role in these findings, but their relationship to changes in
linical outcomes is not known.
cknowledgment
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